These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 3547618)

  • 21. In vitro activities of ciprofloxacin, ofloxacin, norfloxacin and rosoxacin compared with cinoxacin and trimethoprim.
    Digranes A; Dibb WL; Benonisen E
    Chemotherapy; 1985; 31(6):466-71. PubMed ID: 2934234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative in vitro activities of pefloxacin, ofloxacin, enoxacin and ciprofloxacin against 256 clinical isolates.
    Arpi M; Gahrn-Hansen B; Søgaard P; Bentzon MW
    Acta Pathol Microbiol Immunol Scand B; 1987 Apr; 95(2):141-6. PubMed ID: 3473910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative in vitro activity of ciprofloxacin and five other quinoline derivatives against gram-negative isolates.
    Galante D; Pennucci C; Esposito S; Barba D
    Drugs Exp Clin Res; 1985; 11(5):331-4. PubMed ID: 2941260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of the newer quinolones compared with the classic ones and tobramycin.
    Boquet Jiménez E; Dalet Escribá F; Caballé L
    Infection; 1985; 13(4):193-6. PubMed ID: 2931382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Gyrase inhibitor].
    Forth W
    Klin Wochenschr; 1985 Oct; 63(19):1036-9. PubMed ID: 2999503
    [No Abstract]   [Full Text] [Related]  

  • 26. The in-vitro activity of EN 272, a quinolone-7-carboxylic acid, in comparison with other quinolones.
    Neu HC
    J Antimicrob Chemother; 1985 Jul; 16(1):43-8. PubMed ID: 3862659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Refractory respiratory tract infections. 7. Trends in the development of new chemotherapeutic agents for respiratory tract infections. b. Synthetic antibacterial agents].
    Ohno I; Ida S
    Nihon Rinsho; 1987 Mar; 45(3):577-82. PubMed ID: 3298736
    [No Abstract]   [Full Text] [Related]  

  • 28. Ofloxacin: antibacterial activity, induction of resistance and killing curves.
    Husson MO; Izard D; Bryskier A; Leclerc H
    Chemioterapia; 1985 Aug; 4(4):278-83. PubMed ID: 3863716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis.
    Berlin OG; Young LS; Bruckner DA
    J Antimicrob Chemother; 1987 May; 19(5):611-5. PubMed ID: 3112095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro comparison of norfloxacin with nalidixic acid, cinoxacin and oxolinic acid.
    Vuye A
    Arzneimittelforschung; 1983; 33(12):1623-7. PubMed ID: 6230083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.
    Traub WH
    Chemotherapy; 1985; 31(1):34-9. PubMed ID: 3156026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Sensitivity of obligate anaerobes to ofloxacin, pefloxacin, enoxacin and norfloxacin].
    Dubreuil L; Devos J; Romond C; Bryskier A
    Pathol Biol (Paris); 1985 May; 33(5):421-5. PubMed ID: 3162143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms of action of and resistance to ciprofloxacin.
    Hooper DC; Wolfson JS; Ng EY; Swartz MN
    Am J Med; 1987 Apr; 82(4A):12-20. PubMed ID: 3034057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity.
    Schmid DA; Depta JP; Pichler WJ
    Clin Exp Allergy; 2006 Jan; 36(1):59-69. PubMed ID: 16393267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cross resistance of quinolone derivatives in gram-negative bacteria.
    Barba D; Pennucci C; Esposito S; Galante D
    Chemioterapia; 1985 Apr; 4(2):192-6. PubMed ID: 3159488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Inhibition of the maintenance and transfer of antibiotic-resistance plasmids by quinolones].
    Uccelli V; Laporte JM; Michel-Briand Y
    C R Seances Soc Biol Fil; 1985; 179(5):696-9. PubMed ID: 2938699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA; Noone P
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.
    Smith SM
    Antimicrob Agents Chemother; 1986 Feb; 29(2):325-6. PubMed ID: 2940966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of pefloxacin compared with five other quinolones on nalidixic acid-resistant proteae species.
    Piccolomini R; Cellini L; Allocati N; Di Girolamo A; Selan L; Scazzocchio F
    Chemioterapia; 1988 Oct; 7(5):287-91. PubMed ID: 3224396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Susceptibility of Bordetella pertussis to five quinolone antimicrobic drugs.
    Appleman ME; Hadfield TL; Gaines JK; Winn RE
    Diagn Microbiol Infect Dis; 1987 Oct; 8(2):131-3. PubMed ID: 2892608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.